Skeletal muscle relaxants and associated medications for nonspecific acute back pain

P and T

Volumn 30, Issue 9, 2005, Pages 518-526

  Reeves, Roy R ^a,b   Algood, Terrel L ^a   Wise, P Melonee ^a  

^a G V SONNY MONTGOMERY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; ANALGESIC AGENT; ANTIHISTAMINIC AGENT; BACLOFEN; CARISOPRODOL; CENTRAL DEPRESSANT AGENT; CHLORZOXAZONE; CYCLOBENZAPRINE; CYCLOOXYGENASE 2 INHIBITOR; DANTROLENE; DIAZEPAM; LISINOPRIL; METAXALONE; METHOCARBAMOL; MONOAMINE OXIDASE INHIBITOR; MUSCLE RELAXANT AGENT; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; NORGESIC; ORPHENADRINE CITRATE; PARACETAMOL; ROBAXISAL; SPASMOLYTIC AGENT; TIZANIDINE; TRICYCLIC ANTIDEPRESSANT AGENT;

APLASTIC ANEMIA; ATAXIA; BACKACHE; CONSTIPATION; CONVULSION; DISABILITY; DIZZINESS; DROWSINESS; DRUG ABUSE; DRUG EFFICACY; DRUG METABOLISM; HEADACHE; HEMOLYTIC ANEMIA; HUMAN; HYPOTENSION; IRRITABILITY; LIVER TOXICITY; MANIPULATIVE MEDICINE; MUSCLE SPASM; PHYSIOTHERAPY; PRODUCTIVITY; PUBLIC HEALTH; REVIEW; SIDE EFFECT; SKELETAL MUSCLE; SOCIOECONOMICS; SPASTICITY; SYNCOPE; TREMOR; UNITED STATES; URINE RETENTION; VERTIGO; VISUAL IMPAIRMENT; WITHDRAWAL SYNDROME; WORKMAN COMPENSATION; XEROSTOMIA;

EID: 24944562697     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Frymoyer JW. Back pain and sciatica. N Engl J Med 1989;318:291-300.
2. Atlas SJ, Deyo RA. Evaluating and managing acute low back pain in the acute care setting. J Gen Intern Med 2001;16:120-131.
3. Jackson KC. Pharmacotherapy in lower back pain. Drugs Today 2004;40:765-772.
4. rd ed. Philadelphia, PA: FA Davis; 1996:14-59.
5. Cady R, Farmer K, Schreiber C. Special report. Skeletal muscle relaxants: A new rationale for choice. Prim Care Spec Ed 2003;7:1-14.
6. Nachemson AL. The lumbar spine: An orthopedic challenge. Spine 1976;1:59-71.
7. van Tulder MW, Touray T, Furlan AD, et al. Muscle relaxants for nonspecific low back pain: A systematic review within the framework of the Cochrane Collaboration. Spine 2003;28:1978-1992.
8. Rumore MM, Schlichting DA. Analgesic effects of antihistamines. Life Sci 1985;36:403-416.
9. Waldman HJ. Centrally acting skeletal muscle relaxants and associated drugs. J Pain Symptom Manage 1994;9:434-441.
10. Powers BJ, Cattau EL, Zimmerman HJ. Chlorzoxazone hepatotoxic reactions. Arch Intern Med 1986;146:1183-1186.
11. Douglas JF, Ludwig GJ, Schlosser A. The metabolic fate of carisoprodol in the dog. J Pharm Exp Ther 1982;138:21-27.
12. Meyer MC, Straughn A. Meprobamate. J Am Pharm Assoc 1977;17:173-175.
13. Littrell RA, Hayes RA, Stillner V. Carisoprodol (Soma): A new and cautious perspective on an old agent. South Med J 1993;86:753-756.
14. Moore RM, Chua L. Carisoprodol dependence: A case report. Am J Drug Alcohol Abuse 1978;5:527-530.
15. Rust GS, Hatch R, Gums JG. Carisoprodol as a drug of abuse. Arch Fam Med 1993;2:429-432.
16. Sidkar S, Basu D, Malhotra AK, et al. Carisoprodol abuse: A report from India. Acta Psychiatr Scand 1993;88:302-303.
17. Luehr JG, Meyerle KA, Larson EW. Mail-order (veterinary) drug dependence (letter). JAMA 1990;263:657.
18. Littrell RA, Sage T, Miller W. Meprobamate dependence secondary to carisoprodol (Soma) use. Am J Drug Alcohol Abuse 1993;19:133-134.
19. Reeves RR, Pinkofsky HB, Carter OS. Carisoprodol: A drug of continuing abuse. J Am Osteopath Assoc 1997;97:723-724.
20. Elder NC. Abuse of skeletal muscle relaxants. Am Fam Physician 1991;44:1223-1226.
21. Reeves RR, Beddingfield JJ, Mack JE. Carisoprodol withdrawal syndrome. Pharmacotherapy 2004;24:1804-1806.
22. Chou R, Peterson K, Helfand M. Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: A systematic review. J Pain Symptom Manage 2004;28:140-175.
23. Bragstad A, Blikra G. Evaluation of a new skeletal muscle relaxant in the treatment of low back pain (a comparison of DS 103-182 with chloroxazone). Curr Ther Res 1979;26:39-43.
24. Hennies O. A new skeletal muscle relaxant (DS 103-282) compared to diazepam in the treatment of muscle spasm of local origin. J Int Med Res 1981;9:62-68.
25. Lepisto P. A comparison trial of DS 103-282 and placebo in the treatment of acute skeletal muscle spasms due to disorders of the back. Curr Ther Res 1979;26:454-459.
26. Berry H, Hutchinson DR. A multicentre placebo-controlled study in general practice to evaluate the efficacy and safety of tizanidine in acute low-back pain. J Int Med Res 1988;16:75-82.
27. Berry H, Hutchinson DR. Tizanidine and ibuprofen in acute low-back pain: Results of a double-blind multicentre study in general practice. J Int Med Res 1988;16:83-91.
28. Kao CD, Chang JB, Chen JT, et al. Hypotension due to interaction between lisinopril and tizanidine. Ann Pharmacother 2004;38:1840-1843.
29. Rudick RA, Schiffer RB, Herndon RM. Drug treatment of multiple sclerosis. Semin Neurol 1987;7:150-159.
30. Kita M, Goodkin DE. Drugs used to treat spasticity. Drugs 2000;59:487-495.
31. Abbruzzese G. The medical management of spasticity. Eur J Neurol 2002;9(Suppl 1):30-34.
32. Schnitzer TJ, Ferraro A, Hunsche E, Kong SK. A comprehensive review of clinical trials on the efficacy and safety of drugs for the treatment of low back pain. J Pain Symptom Manage 2004;28:72-95.
33. van Tulder MW, Scholten RJPM, Koes BW, Deyo RA. Non-steroidal anti-inflammatory drugs for low back pain. Spine 2000;25:2501-2513.
34. van Tulder MW, Koes BW, Bouter LM. Conservative treatment of acute and chronic nonspecific low back pain. Spine 1997;22:2128-2156.
35. Cherkin CD, Sherman KJ, Deyo RA, Shekelle PG. A review of the evidence for the effectiveness, safety, and cost of acupuncture, massage, and spinal manipulation for back pain. Ann Intern Med 2003;138:898-906.
36. Haizlip TM, Ewing JA. Meprobamate habituation. N Eng J Med 1958;258:1181-1186.
37. Reeves RR, Carter OS, Pinkofsky HB. Use of cariosprodol by substance abusers to modify the effects of illicit drugs (letter). South Med J 1999;92:441.
38. Chop WM. Should carisoprodol be a controlled substance (letter)? Arch Fam Med 1993;2:911.
39. Reeves RR, Liberto V. Abuse of combinations of cariosprodol and tramadol. South Med J 2001;94:512-524.
40. Davis GG, Alexander BA. A review of carisoprodol deaths in Jefferson County, Alabama. South Med J 1998;91:726-730.
41. Reeves RR, Carter OS, Pinkofsky HB, et al. Carisoprodol (Soma): Abuse potential and physician unawareness. J Addictive Dis 1999;18:51-56.
42. Preston KL, Guarino JJ, Kirk WT, Griffiths RR. Evaluation of the abuse potential of methocarbamol. J Pharmacol Exp Ther 1989;248:1146-1157.
43. Preston KL, Wolf B, Guarino JJ, Griffiths RR. Subjective and behavioral effects of diphenhydramine, lorazepam, and methocarbamol: Evaluation of abuse liability. J Pharmacol Exp Ther 1992;262:707-720.
44. May CR. Baclofen overdosed. Ann Emerg Med 1983;12:171-173.
45. Schiafano F, Marra R, Magni G. Orphenadrine abuse (letter). South Med J 1988;81:546-547.
46. Skolnick N. Abuse potential of skeletal muscle relaxants. Resident Staff Physician September, 2000:19-23.
47. Elenbaas JK. Centrally acting skeletal muscle relaxants. Am J Hosp Pharm 1980;37:1313-1323.